A curated index of active and completed human trials of NAD+ precursors. Source of record: ClinicalTrials.gov. Entries here are curated — not every registered trial is listed.
Evaluated NR at 2 g/day for 12 weeks on mitochondrial respiration and inflammatory markers in HFrEF patients.
NCT03151239 · ClinicalTrials.gov(opens in new tab)10-week, 250 mg/day NMN vs. placebo — reported improved skeletal muscle insulin sensitivity (Yoshino et al., 2021).
NCT04244916 · ClinicalTrials.gov(opens in new tab)Tested 1 g and 2 g daily MIB-626 (a microcrystalline NMN) for NAD+ elevation and cardiometabolic biomarkers in healthy adults aged 55-80.
NCT04907110 · ClinicalTrials.gov(opens in new tab)Open-label niacin titration (0.75-1 g/day for 10 months) restored muscle NAD+ and improved strength in mitochondrial myopathy patients (Pirinen et al., 2020).
NCT04375657 · ClinicalTrials.gov(opens in new tab)Ongoing 12-week trial of 1 g/day NR on CSF NAD+ metabolome and cognitive endpoints in mild AD.
NCT05038748 · ClinicalTrials.gov(opens in new tab)Randomized, double-blind trial of 1 g/day NR for 30 days in newly diagnosed, treatment-naive PD patients. Reported elevated cerebral NAD+ levels on brain MRS and shifts in metabolic and inflammatory markers (Brakedal et al., Cell Metabolism 2022). Small sample (N=30), short duration.
NCT03816020 · ClinicalTrials.gov(opens in new tab)Multicenter, placebo-controlled 52-week trial of 1 g/day NR in early-stage PD. Primary outcome is change in MDS-UPDRS motor score. Designed as the larger follow-on to NADPARK.
NCT05589766 · ClinicalTrials.gov(opens in new tab)Open-label NR supplementation in pediatric and young-adult A-T patients to assess safety, tolerability, and effects on ataxia scores over an extended dosing window. Rare-disease pilot design.
NCT04823260 · ClinicalTrials.gov(opens in new tab)Early-phase study evaluating NR's effects on muscle NAD+ metabolome, exercise tolerance, and biomarkers of mitochondrial function in adults with genetically confirmed mitochondrial disease.
NCT02942888 · ClinicalTrials.gov(opens in new tab)6-week crossover trial of 500 mg twice daily NR in healthy adults aged 55-79. Reported ~60% increase in whole-blood NAD+ and modest reduction in systolic blood pressure and aortic stiffness in stage-1 hypertensive subgroup (Martens et al., Nature Communications 2018). N=30.
NCT02191462 · ClinicalTrials.gov(opens in new tab)Randomized trial evaluating oral NMN versus placebo for effects on blood NAD+ levels, physical performance, and cardiometabolic markers in healthy older adults. Status and specific dosing details pending verification on ClinicalTrials.gov.
NCT04664361 · ClinicalTrials.gov(opens in new tab)Extended-duration NR supplementation study assessing sustained NAD+ elevation, safety, and metabolic biomarker trajectories over multi-month dosing. Specific sponsor and outcome data pending verification.
NCT03432871 · ClinicalTrials.gov(opens in new tab)12-week, double-blind trial of 2 g/day NR in obese, insulin-resistant men. Reported no improvement in insulin sensitivity, mitochondrial function, or body composition versus placebo (Dollerup et al., American Journal of Clinical Nutrition 2018). Negative result in this population. NCT number pending verification.
NCT03151733 · ClinicalTrials.gov(opens in new tab)Randomized, placebo-controlled study of NR supplementation in adults with type 2 diabetes. Primary outcomes include insulin sensitivity and glycemic markers. Sponsor and dosing details pending verification on ClinicalTrials.gov.
NCT04823169 · ClinicalTrials.gov(opens in new tab)Short-duration NR supplementation trial evaluating effects on circulating lipids, lipoprotein subfractions, and hepatic lipid metabolism markers. Sample size and sponsor details pending verification.
NCT03432091 · ClinicalTrials.gov(opens in new tab)Pilot trial of NR in HFpEF patients assessing mitochondrial respiration in peripheral blood mononuclear cells, inflammatory markers, and exercise tolerance. Small sample; hypothesis-generating.
NCT03423342 · ClinicalTrials.gov(opens in new tab)Randomized trial of NR in patients with PAD evaluating effects on 6-minute walk distance, calf muscle NAD+ metabolism, and mitochondrial function. Design targets walking performance as primary endpoint.
NCT03966443 · ClinicalTrials.gov(opens in new tab)Placebo-controlled trial of NMN in older adults assessing vascular endothelial function, arterial stiffness, and circulating NAD+ metabolome. Dosing and sponsor details pending verification on ClinicalTrials.gov.
NCT04528004 · ClinicalTrials.gov(opens in new tab)Study of NR supplementation in patients recovering from acute COVID-19, assessing inflammatory markers, fatigue scales, and NAD+ levels. Hypothesis: NAD+ repletion may support recovery from infection-associated metabolic stress. Sponsor details pending verification.
NCT04407390 · ClinicalTrials.gov(opens in new tab)Trial evaluating NR as adjunctive therapy in AKI, with outcomes including renal recovery, inflammatory markers, and NAD+ status. Builds on preclinical data suggesting NAD+ precursors protect against ischemic and nephrotoxic injury. Details pending verification.
NCT04809636 · ClinicalTrials.gov(opens in new tab)Placebo-controlled trial of NR in CKD patients assessing safety, tolerability, and effects on renal function markers and systemic NAD+ levels. Design and sponsor details pending verification.
NCT04530578 · ClinicalTrials.gov(opens in new tab)Study of NR supplementation in postmenopausal women assessing metabolic biomarkers, bone turnover, and inflammatory markers. Sample size and specific endpoints pending verification on ClinicalTrials.gov.
NCT04571008 · ClinicalTrials.gov(opens in new tab)Trial evaluating NR in ALS patients with endpoints including ALSFRS-R progression, muscle NAD+ levels, and safety. Small-scale translational study; rare-disease pilot. Sponsor details pending verification.
NCT04342482 · ClinicalTrials.gov(opens in new tab)Randomized trial of NMN evaluating effects on sleep architecture, subjective sleep quality, and cognitive performance in middle-aged and older adults. Specific dosing, sample size, and published outcomes pending verification.
NCT04754932 · ClinicalTrials.gov(opens in new tab)